Different assessments of immunohistochemically stained Ki-67 and hTERT in glioblastoma multiforme yield variable results: A study with reference to survival prognosis

Clinical Neuropathology

Volumn 27, Issue 4, 2008, Pages 224-233

  Persson, A ^a   Englund, E ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Correlation; Glioblastoma multiforme; Immunohistochemical ki 67; Length of survival age

Indexed keywords

DNA; FORMALDEHYDE; KI 67 ANTIGEN; PARAFFIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

AGE OF ONSET; AGED; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROGNOSIS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 47349129485     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/npp27224     Document Type: Article

References (41)

1. Blackburn EH. Structure and function of telomeres. Nature. 1991; 350: 569-573.
2. Boldrini L et al. Telomerase activity and hTERT mRNA expression in glial tumors. Int J Oncol. 2006; 28: 1555-1560.
3. Bredel M et al. High expression of DNA topoisomerase IIalpha and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. European Journal of Cancer. 2002; 38: 1343-1347.
4. Cabuy E, de Ridder L. Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo. Virchows Archiv. 2001; 439: 176-184.
5. Callaert H. Comparing statistical software packages: The case of the logrank test in StatXact. The American Statistican. 2003; 57: 214-217.
6. Chakravarti A et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res. 2001; 7: 2387-2395.
7. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society. Series B (Methodological). 1972; 34: 187-220.
8. Deckert M et al. Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol. 1989; 115: 179-188.
9. Falchetti ML et al. Telomerase in brain tumors. Child's Nervous System. 2002; 18: 112-117.
10. Falchetti ML et al. In situ detection of telomerase catalytic subunit mRNA in glioblastoma multiforme. International Journal of Cancer. 2000; 88: 895-901.
11. Fukushima T et al. Prediction of clinical course of diffusely infiltrating astrocytomas from telomerase expression and quantitated activity level. Cancer Lett. 2002; 187: 191-198.
12. Gerdes J et al. Immunohistological detection of tumor growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol. 1992; 168: 85-86.
13. Harada K et al. Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker. J Neurosurg. 2000; 93: 618-625.
14. Hiraga S et al. Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res. 1998; 58: 2117-2125.
15. Hiyama E et al. Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues. Neoplasia. 2001; 3: 17-26.
16. Hiyama E, Hiyama, K.. Telomerase as tumor marker. Cancer Letters. 2003; 194: 221-233.
17. Ho DM et al. MIB-1 and DNA topoisomerase II alpha could be helpful for predicting long-term survival of patients with glioblastoma. Am J Clin Pathol. 2003; 119: 715-722.
18. Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Computational Statistics and Data Analysis. 2003; 43: 121-137.
19. Kleihues PCW. World Health Organization Classification of Tumors. Pathology and Genetics. Tumors of the nervous system. Lyon: IARC Press; 2000.
20. Kleinschmidt-DeMasters BK et al. Quantitative telomerase expression in glioblastomas shows regional variation and down-regulation with therapy but no correlation with patient outcome. Human pathology. 2000; 31: 905-913.
21. Kotoula V et al. hTERT immunopositivity patterns in the normal brain and in astrocytic tumors. Acta Neuropathol (Berl). 2006; 111: 569-578.
22. Kowalczuk A et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery. 1997; 41: 1028-1036; discussion 1036-1028.
23. Kraus JA et al. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. J Neurooncol. 2001; 52: 263-272.
24. Lacroix M et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001; 95: 190-198.
25. Miracco C et al. In situ detection of telomeres by fluorescence in situ hybridization and telomerase activity in glioblastoma multiforme: correlation with p53 status, EGFR, c-myc, MIB1, and Topoisomerase IIalpha protein expression. Int J Oncol. 2003; 23: 1529-1535.
26. Moskowitz SI et al. Role of MIB1 in Predicting Survival in Patients with Glioblastomas. J Neurooncol. 2006; 76: 193-200.
27. Moyzis RK et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proceedings of the National Academy of Sciences of the United States of America. 1988; 85: 6622-6626.
28. Nakatani K et al. The significant role of telomerase activity in human brain tumors. Cancer. 1997; 80: 471-476.
29. Neder L et al. MIB-1 labeling index in astrocytic tumors - a clinicopathologic study. Clin Neuropathol. 2004; 23: 262-270.
30. Reavey-Cantwell JF et al. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. Journal of Neuro-Oncology. 2001; 55: 195-204.
31. Saito T et al. Prognosis of cerebellar glioblastomas: correlation between prognosis and immunoreactivity for epidermal growth factor receptor compared with supratentorial glioblastomas. Anticancer Res. 2006; 26: 1351-1357.
32. Sallinen PK et al. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol. 1994; 174: 275-282.
33. Sarkar C et al. Supratentorial glioblastoma in adults: identification of subsets and their clinical correlation. Brain Tumor Pathol. 2004; 21: 7-12.
34. Schiffer D. Brain tumor pathology: Current diagnostic hotspots and pitfalls. Dordrecht, the Netherlands: Springer; 2006.
35. 22 and correlation with survival in initial and recurrent human gliomas. Journal of NeuroOncology. 2004; 67: 29-39.
36. Tchirkov A et al. Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Br J Cancer. 2003; 88: 516-520.
37. Wakimolo H et al. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer. 1996; 77: 373-380.
38. Wang L et al. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol. 2006; 24: 1627-1632.
39. Vaquero J et al. Prognostic significance of endothelial surface score and MIB-1 labeling index in glioblastoma. Journal of Neuro-Oncology. 2000; 46: 11-16.
40. Wright WE, Shay JW. Telomere biology in aging and cancer. Journal of the American Geriatrics Society. 2005; 53: S292-S294.
41. Yan P et al. Immunohistochemical localization of hTERT protein in human tissues. Histochemistry & Cell Biology. 2004; 121: 391-398.